Project: BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients
Moberg Pharma and partners will further develop and commersialise BUPI - an innovative and superior long-acting treatment for cancer patients suffering from pain associated with Oral Mucositis (OM). BUPI will be evaluated in a phase III trial. The project will deliver a final product ready for registration and thereafter launch – with documented benefits for patients.
| Acronym | BUPI (Reference Number: 9794) |
| Duration | 01/10/2015 - 01/10/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |